Laennec, 2 ml 10 pcs

Laennek is a new unique remedy, which promotes rejuvenation of the body and restoration of health, is an immunomodulator, hepatoprotector, promotes immunity.

The preparation exhibits immunomodulatory properties due to the ability to stimulate humoral immunity and increase the functional activity of phagocytes and natural killers. It increases bactericidal activity of leukocytes of peripheral blood which shows its ability to destroy invaded pathogen. Cytokines contained in the drug activate the metabolic and supervising functions of skin cells.

The biologically active substances contained in the hydrolyzate stimulate the regeneration (proliferation) of hepatocytes, exhibit detoxifying properties, reduce deposition of lipids and cholesterol in liver cells, increase the activity of tissue respiration, activate metabolism in the liver, reduce the intensity of connective tissue in the liver.

Indications

Active ingredient

Composition

Injection solution.

1 ampoule contains:

Active substance:

Human placenta hydrolysate 112 mg

Associates:

water for injection,

sodium hydroxide or hydrochloric acid (to correct pH).

How to take, the dosage

In chronic recurrent herpes and atopic dermatitis the drug is administered by IV drop: 10 ml (560 mg of placenta hydrolysate) of the drug (5 ampoules) are dissolved in 250-500 ml of 5% dextrose solution or physiological solution and injected through the ulnar vein for 1.5-2 hours. Injections are given 3 times a week at 2-day intervals. The course of treatment is 10 injections.

In chronic liver diseases (steatohepatitis /alcoholic, metabolic and mixed etiology/) the drug is administered in/m 2 ml/day (112 mg of placenta hydrolysate). Depending on the severity of the disease, frequency of injections can be increased up to 2-3 times (6 ml)/day. The drug can be administered by IV drop: 10 ml (560 mg of placenta hydrolysate) of the drug (5 ampoules) are dissolved in 250-500 ml of 5% dextrose solution or physiological solution and injected through the ulnar vein for 1.5-2 hours. Injections are carried out twice a week. The course of treatment is 2-3 weeks.

Interaction

Laennek solution mixed with other drugs that are strong bases (pH above 8.5) decreases the activity of the drug.

To date no other clinically significant drug interactions have been identified.

Special Instructions

According to currently available data, the drug can be administered to the elderly. However, given that physiological functions worsen in the elderly, the drug should be used under close supervision.

Paediatric use

Studies on the safety of Laennec in infants (including premature infants) and juveniles have not been conducted. The use in children is not recommended.

Contraindications

With caution, use in patients with polyvalent allergy to drugs, the elderly.

Side effects

Side effects have been reported in 3.7% of patients.

Clinically significant adverse reactions: allergic reactions possible.

Other adverse events: soreness at the injection site (2.56%), allergic reactions (redness, itching) (0.37%), numbness at the injection site (0.37%), gynecomastia (0.37%) – no causal relationship with the drug administration was found.

Overdose

There are currently no reported cases of overdose of Laennek.